Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-08 · accession 0001967150-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-01-12 | 2026-01-08+ | ELVN | Lyssikatos Joseph P | CSO | S - Sale | $26.23 | -132.5K | 765.2K | -15% | -$3.48M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-08 | S | D | 7,500 | $20.13 | 890,188 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 2 | Common | Common Stock | 2026-01-08 | S | D | 33,802 | $24.92 | 856,386 | I See footnote | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 3 | Common | Common Stock | 2026-01-09 | S | D | 41,198 | $24.90 | 815,188 | I See footnote | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 4 | Common | Common Stock | 2026-01-09 | S | D | 50,000 | $29.13 | 765,188 | I See footnote | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |